Facts & Figures

The Innovative Medicine Initiative (IMI) is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.

Full project title	Psychiatric Ratings using Intermediate Stratified Markers 2 (PRISM 2)
Start date	1 June 2021
Duration	3 years
Total costs	7.89 million €
Project coordinator	Prof. Dr. Martien Kas (RUG)
Project leader	Dr. Hugh Marston (BI)
Number of work packages	6
Fact sheet	online project information by the funding agency
Funding source	Innovative Medicines Initiative (IMI) 2 Joint Undertaking (IMI2 JU): European Union’s Horizon 2020 research and innovation programme, EFPIA and Cohen Veterans Bioscience (CVB)

**Map of project members:** PRISM 2 partners are distributed throughout Europe and the United States.

The PRISM 2 project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101034377. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, EFPIA, and Cohen Veterans Bioscience (CVB). The website reflects only the authors' views and IMI JU, EFPIA, CVB, and the European Commission are not responsible for any use that may be made of the information it contains.